ANVS Annovis Bio, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1477845 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-107.9%
TTM EPS YoY-8.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-455.9%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets340.5%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio36.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $25.22M | $20.00M | $38.79M | $16.52M | $8.48M |
| SG&A expense | $4.48M | $6.70M | $6.24M | $9.00M | $6.06M |
| Operating income | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -$14.54M |
| Pretax income | — | — | -$56.20M | -$25.33M | -$14.49M |
| Income tax | $0 | — | — | — | — |
| Net income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M |
| EPS (basic) | -1.40 | -2.02 | -6.23 | -3.10 | -1.90 |
| EPS (diluted) | -1.40 | -2.31 | -6.23 | -3.10 | -1.90 |
| Weighted avg. shares (diluted) | 20.55M | 12.24M | 9.02M | 8.16M | 7.63M |
| Balance sheet | |||||
| Cash & equivalents | $19.53M | $10.55M | $5.75M | $28.38M | $45.69M |
| Current assets | — | — | $10.21M | $36.02M | $46.00M |
| Total assets | $21.08M | $13.93M | $10.21M | $36.02M | $46.00M |
| Current liabilities | $3.64M | $3.88M | $4.28M | $7.70M | $1.51M |
| Total liabilities | $4.23M | $4.62M | $17.96M | $7.70M | $1.51M |
| Shareholders' equity | $16.85M | $9.31M | -$7.75M | $28.32M | $44.49M |
| Shares outstanding | 27.20M | 14.14M | 10.52M | 8.16M | 8.10M |
| Cash flow statement | |||||
| Operating cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M |
| Financing cash flow | $34.60M | $26.69M | $17.34M | $4,613 | $46.74M |
| Stock-based compensation | $1.80M | $3.84M | $4.63M | $9.15M | $4.70M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.